Navigation Links
BioLife Solutions Presents Data on CryoStor at International,Society for Cellular Therapy Annual Meeting

will continue our evaluations and validation of BioLife's products with the hope to incorporate CryoStor into our clinical applications."

BioLife Chief Executive Mike Rice remarked: "We're very pleased that world-class institutions like the Fred Hutchinson Cancer Research Center and the University of Washington have confirmed the value of BioLife's intellectual property and CryoStor products which provide unique benefits to clinicians in their fight against cancer and other diseases. The data from this independent comparative evaluation of CryoStor is consistent with results of our internal research. Awareness of our enabling technology is growing as clinical researchers and care givers realize how our proprietary products can enhance their biologic-based therapies and services."

According to an August 2006 research report published by Jain PharmaBiotech, the total value of cell-based markets was $27 billion in 2005 and is expected to grow to $96 billion in 2015, as more than 300 companies are engaged in developing cell-based alternatives to medical devices and drugs to treat and possibly cure numerous acute and chronic diseases. Additionally, PA Consulting Group, a global consulting firm with expertise in life sciences and healthcare, estimates the worldwide market for media to preserve cells,

tissues, and organs for research and clinical applications will grow to from $200 million in 2007 to more than $300 million by 2011.

About BioLife Solutions

BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells, tissues, and organs. The Company's proprietary HypoThermosol(R) and CryoStor(TM) platform of solutions are marketed to academic and commercial organizations involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce preservat
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Ties Between Physicians and Drug Companies Still Too Strong: the Prescription Project Offers Solutions to Prevent Conflicts of Interest
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:12/1/2008)... Md., Dec. 1 Vanda Pharm...ion in The Lancet , one of the world,s leading me...novel circadian regulator, experimental compound t...am et al(1) is entitled "Melatonin agonist tasimel...time shift: two randomised controlled multicentre ...
(Date:12/1/2008)...tudy shows the Prox1 gene is a two-way switch that...s to be reprogrammed so that they lose their ident..., , MEMPHIS, Tenn., Dec. 1 /PRNewswire-USNew...rch Hospital have discovered that a certain differ...ity that it requires the constant expression of a ...
(Date:12/1/2008)...ec. 1 GeoVax Labs, Inc.,...echnology company developing,human vaccines for d...rus) and,other infectious agents, announced today...ials will take place in twelve sites across North ...collaboration with The National Institutes of,Hea...
(Date:11/28/2008)...IS, Nov. 28 Eli Lilly an...mental New Drug Application (sNDA) from,the U.S. ... (duloxetine HCl),for the management of chronic p...he first half of 2009, adding data from a recently...is pain of the knee. , The decision does no...
Breaking Medicine Technology:Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Chocolate Milk 3A The Official Drink of Halloween 2863 1Chocolate Milk 3A The Official Drink of Halloween 2863 2Chocolate Milk 3A The Official Drink of Halloween 2863 3Chocolate Milk 3A The Official Drink of Halloween 2863 4Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 2858 1Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 2858 2Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 2858 3Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 1Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 2Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 3Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 4Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 5Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 6Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 1Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 2Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 3Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 4Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 5Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 6
...duces TNF-alpha Production Through Inhibition,of P...ewswire/ -- Anacor,Pharmaceuticals, a privately he...ults from its placebo-controlled Phase 1 trial of,...estigation for,the treatment of psoriasis. The tri...ty comparable to existing topical,treatments for p...
... York, June 06, 2007 /PRNewswire-FirstCall/,-- XTL...as,completed the analysis of results from a Phase ...ronic Hepatitis C. This Phase I,trial was a placeb...hich evaluated the safety, tolerability and antivi...125. The study enrolled 56,patients into seven coh...
Other Medicine Technology:Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory,Compound, Shows Efficacy in Psoriasis 2XTL Provides Update on Phase I Clinical Trial of XTL-2125 2XTL Provides Update on Phase I Clinical Trial of XTL-2125 3
(Date:12/2/2008)... NDA with FDA in Early to Mid-2009 , , WARR...velopers of PharmFilm(R) technology and a drug del... pharmaceutical products, and Strativa Pharmaceuti...rmaceutical Companies, Inc. (NYSE: PRX ), today ... bioequivalence studies for a thin film formulatio...
(Date:12/2/2008)...c. 2 With the bright lights, sweet...holidays may be an exciting time of year for any c..., especially with today,s tough economy. Whether ...ptying their wallets, or spending hours traveling ...elax, and even less time to be alone and romantic ...
(Date:12/2/2008)...Dec. 2 Aduromed Industri...ovider of medical waste treatment,systems, today ... on November,24, 2008 to protect the Company,s pr...nerized MedClean Systems that provide a turnkey so...zation and volume reduction. , The patent a...
(Date:12/2/2008).... 2 Mylan Inc. (NYSE: ... Mylan Pharmaceuticals Inc., have entered,into a ... Corp., Novartis,Corp. and Novartis International...sion of Novartis, Femara(R). , Mylan,s Vice...re very,pleased to have reached this agreement, w...
Breaking Medicine News(10 mins):Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 2Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 3Health News:Jennie Finch Shares how to Fire up the Romance Despite the Demands of the Holidays 2Health News:Jennie Finch Shares how to Fire up the Romance Despite the Demands of the Holidays 3Health News:Aduromed Files Patent Application to Cover Proprietary New Standard for Containerized, Turnkey Solution 2Health News:Aduromed Files Patent Application to Cover Proprietary New Standard for Containerized, Turnkey Solution 3Health News:Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity 2
... the risk of diabetes in the Indigenous population...ott, Pro-vice Chancellor of the Division of Health...ows that while clinical care of adults with diabet...ndigenous Australians are developing the disease. ...
... epidemic of diabetes in the US is out. Spending o.... According to a drug trend report released by th...ailed only cholesterol medications in total prescr...n 2006. An aging population and the alarming rise...
...disfiguring accident that nearly killed him, but h...s home on Andrews Air Force Base in Maryland. N...e, that is, because of his brand-new nose. In a s... over a year-long period that ended with removal o...
...al Boston) and colleagues have identified the canc... soft-tissue sarcoma of childhood. 'Identifying ...ved genetic programs underlying self-renewal in ER... into how to destroy these cell types in establish...
Other Medicine News:Health News:Spending on Diabetes Drugs Soars in US 2Health News:Surgeons Perform Nasal Reconstruction for War Veteran Using His Own Body Parts 2Health News:Surgeons Perform Nasal Reconstruction for War Veteran Using His Own Body Parts 3Health News:Surgeons Perform Nasal Reconstruction for War Veteran Using His Own Body Parts 4Health News:Pediatric Cancer Stem Cell Identified 2
Bard Coude-Tip Latex Urethral Catheter, Two Eyes (Tiemann Model)
Used for stone manipulation and removal in the urinary tract. Supplied sterile in peel-open packages. Intended for one-time use.
The Coude tip design facilitates negotiation of the prostatic urethra. It is available in a medium length olive Coude tip with a single drainage eye. The red latex construction provides added stiffne
BARDEX Red Rubber Urethral Catheter (Robinson Model)
Medicine Products: